GLP-1 receptor agonist medications such as semaglutide and tirzepatide have transformed weight management. They are prescription-only medicines, prescribed and monitored by licensed providers. But a question hangs over every treatment plan: what happens when the medication stops?

What the clinical trials found

The clearest answer comes from the STEP 1 trial extension, published in Diabetes, Obesity and Metabolism. Participants who took semaglutide for 68 weeks lost an average of 17.3 percent of their body weight. Then treatment was withdrawn — and over the following year, they regained an average of two-thirds of the weight they had lost. By week 120 they were only 5.6 percent below their starting weight. Regain was fastest among people who had lost the most, though the pace appeared to slow toward the end of the year. One encouraging note: 48.2 percent of participants were still at least 5 percent below their baseline weight a full year after stopping.

Tirzepatide tells a similar story

The SURMOUNT-4 trial, published in JAMA, tested what happens after 36 weeks of tirzepatide. Among 670 participants, half continued the medication for another 52 weeks and half switched to placebo. Those who continued kept losing; among those who stopped, most regained 25 percent or more of the weight they had lost within a year, according to a post hoc analysis in JAMA Internal Medicine.

It is not just the number on the scale

In both trials, health improvements retreated along with the weight. In STEP 1, blood pressure, triglycerides and C-reactive protein moved back toward their pre-treatment levels. The SURMOUNT-4 analysis found that participants who regained the most weight saw the greatest reversal of their cardiometabolic improvements. The STEP 1 authors concluded that the findings "confirm the chronicity of obesity" — in other words, obesity behaves like a chronic condition that needs ongoing management, not a short-term problem with a short-term fix.

The real world looks a little different

A Cleveland Clinic study of 7,938 adults who stopped semaglutide or tirzepatide found that roughly 45 percent maintained or even continued their weight loss one year later. The difference from the trials? In real life, people do not simply stop and do nothing. In the study, 27 percent switched to an alternative obesity medication, 20 percent restarted their original drug, and 14 percent engaged in lifestyle interventions such as dietitian visits and exercise. The researchers also noted that real-world discontinuation is usually driven by cost, insurance issues or side effects — and advised that anyone who needs to stop should discuss alternatives with their clinician.

Why maintenance planning matters

The research points to one practical conclusion: the end of a GLP-1 prescription should be a planned transition, not an abrupt stop. That plan might include a different medication, a structured nutrition and strength-training routine, regular follow-up visits, or some combination. What it should not be is improvised. If you are taking a GLP-1 or thinking about stopping one, talk with your prescriber first about what your maintenance phase will look like.

Sources: Diabetes, Obesity and Metabolism (STEP 1 trial extension, Wilding et al., 2022); JAMA and JAMA Internal Medicine (SURMOUNT-4 trial and post hoc analysis); Cleveland Clinic; Medical News Today.

*This article is presented by Healthy Sprays. Its THIN oral semaglutide spray is a prescription-only product that some patients discuss with their providers when planning the maintenance phase after GLP-1 treatment, and PrescriberNow offers online provider visits for exactly that conversation. Learn more at healthysprays.com and prescribernow.com.*